COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Virtual Health Sciences Library

  • Home
  • Search
  • Knowledge Base
  • Get a journal indexed in the Index Medicus
  • MyVHSL
  1. Home
  2. IMEMR
  3. Search Result
  4. The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: a pilot randomized, double-blind, placebo-controlled trial

The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: a pilot randomized, double-blind, placebo-controlled trial

Authors

Mirzabeigi Parastoo
Mohammadpour, Amir Hooshang
Salarifar, Mojtaba
Gholami, Kheirollah
Mojtahedzadeh, Mojtaba
Javadi, Mohammad Reza
Tehran University of Medical Sciences ; , School of Pharmacy ; , Department of Clinical Pharmacy ;

Iran. J. Pharm. Res. 2015; 14 (2): 479-486
IJPR-Iranian Journal of Pharmaceutical Research
Journal Country: Islamic Republic of Iran
P-ISSN: 1735-0328
E-ISSN: 1726-6890
Type of Publication: Randomized Controlled Trial
Type of Research: Experimental Studies
Keywords: Curcumin / Pharmacology
Broad Subjects: Noncommunicable Diseases, Coronary Artery Disease ,Cardiovascular System ,Double-Blind Method ,Placebos ,C-Reactive Protein ,Lipids ,Blood Glucose
Citation: Parastoo Mirzabeigi ,Amir Hooshang Mohammadpour ,Mojtaba Salarifar ,Kheirollah Gholami ,Mojtaba Mojtahedzadeh ,Mohammad Reza Javadi , The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: a pilot randomized, double-blind, placebo-controlled trial, Iran. J. Pharm. Res. 2015; 14 (2): 479-486

Abstract English

Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovascular risk factors in patients with coronary artery disease [CAD] . A total of 33 patients with CAD who fulfilled inclusion and exclusion criteria were entered the study. Patients were randomly assigned to receive curcumin or placebo, 500 mg capsules, four times daily for 8 weeks. Lipid profile, blood glucose and high sensitive C-reactive protein [hs-CRP] levels were analyzed at baseline and two months after treatment. Serum levels of triglycerides [P=0.01] , LDL-cholesterol [P=0.03] and VLDL-cholesterol [P=0.04] significantly decreased in the curcumin group compared to baseline, without significant changes in total cholesterol, HDL-cholesterol, blood glucose and hs-CRP levels. In all mentioned laboratory parameters, significant difference was not detected between curcumin and placebo. Although curcumin improved some of lipid profile components, it did not show appreciable effect on inflammatory markers in patients with CAD. Therefore, more detailed assessment of metabolic effects or anti-inflammatory activities of curcumin need to perform by extensive human study

Full Text English

Subscribe to VHSL Newsletters

© 2020 WHO – EMRO